Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Increasing evidence suggests that bone marrow‐derived mesenchymal stem cells (MSCs) are recruited into the stroma of developing tumors where they contribute to cancer progression. MSCs produce different growth factors that sustain tumor‐associated neo‐angiogenesis. Since the majority of carcinomas secrete ligands of the epidermal growth factor receptor (EGFR), we assessed the role of EGFR signaling in regulating the release of angiogenic factors in MSCs. Treatment of human primary MSCs and of the human osteoblastic cell line hFOB with transforming growth factor α (TGF‐α), one of the main ligands of the EGFR, significantly induced activation of this receptor and of different intracellular signaling proteins, including the PI3K/AKT and the MEK/MAPK pathways. TGF‐α induced a significant increase in the levels of secretion of vascular endothelial growth factor in both MSCs and hFOB. Conditioned medium from TGF‐α treated MSCs showed an higher in vivo angiogenic effect as compared with medium from untreated cells. Treatment of MSCs with TGF‐α also produced a significant increase in the secretion of other angiogenic growth factors such as angiopoietin‐2, granulocyte‐colony stimulating factor, hepatocyte growth factor, interleukin (IL)‐6, IL‐8, and platelet‐derived growth factor‐BB. Using selective MEK and PI3K inhibitors, we found that both MEK/MAPK and the PI3K/AKT signaling pathways mediate the ability of TGF‐α to induce secretion of angiogenic factors in MSCs. Finally, stimulation with TGF‐α increased the ability of MSCs to induce migration of MCF‐7 breast cancer cells. These data suggest that EGFR signaling regulates the ability of MSCs to sustain cancer progression through the release of growth factors that promote neo‐angiogenesis and tumor cell migration. J. Cell. Physiol. 226: 2131–2138, 2011. © 2010 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684 · cited 1×
“Recent reports suggest that tumor-derived soluble factors might regulate in MSCs as well as in TAFs the production of molecules that are involved in tumor growth and in angiogenesis (Karnoub et al., 2007; Mishra et al., 2008; Spaeth et al., 2009).”
BackgroundMesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953 · cited 1×
“Evidence suggests that coating by pericytes helps the tumor endothelium to survive and function even in the absence of VEGF, and thereby enables tumors to grow during the course of an anti-angiogenic therapeutic regimen (Bergers and Hanahan, 2008).”
BackgroundAngiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653 · cited 3×
“This latter cell type plays an important role in cancer progression by promoting angiogenesis, epithelial to mesenchymal transition, and genetic instability (Hall et al., 2007).”
BackgroundBissell, M. J., & Radisky, D. (2001) · Nature Reviews Cancer · doi:10.1038/35094059 · Cited by 2,180
Tumor Self-Seeding by Circulating Cancer Cells
Kim, M.-Y., Oskarsson, T., Acharyya, S., Nguyen, D. X., Zhang, X. H.-F., Norton, L., & Massagué, J. (2009) · Cell · doi:10.1016/j.cell.2009.11.025 · Cited by 1,335
Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells
Mishra, P. J., Mishra, P. J., Humeniuk, R., Medina, D. J., Alexe, G., Mesirov, J. P., Ganesan, S., Glod, J. W., & Banerjee, D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0943 · Cited by 912 · cited 3×
“These cells differ from a normal fibroblastic phenotype by exhibiting specificmyofibroblastic characteristics and representing a richer source of tumor-growth-promoting factors, including pro-angiogenic molecules (Mishra et al., 2008; Spaeth et al., 2009).”
BackgroundSpaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., Andreeff, M., & Marini, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004992 · Cited by 807
Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells
Sullivan, N. J., Sasser, A. K., Axel, A. E., Vesuna, F., Raman, V, Ramirez, N., Oberyszyn, T. M., & Hall, B. M. (2009) · Oncogene · doi:10.1038/onc.2009.180 · Cited by 757
Interleukin‐6 is a potent growth factor for ER‐α‐positive human breast cancer
Sasser, A. K., Sullivan, N. J., Studebaker, A. W., Hendey, L. F., Axel, A. E., & Hall, B. M. (2007) · The FASEB Journal · doi:10.1096/fj.07-8832com · Cited by 222 · cited 1×
“It has been previously demonstrated that IL-6 and VEGF can sustain the growth of different breast cancer cell lines including MCF-7 cells, which express receptors for both these growth factors (Sasser et al., 2007;Wu et al., 2006; Sullivan et al., 2009).”
Background
Cited by
Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine
Vizoso, F., Eiro, N., Cid, S., Schneider, J., & Perez-Fernandez, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091852 · Cited by 1,363
“Likewise, CM from MSCs treated with TFG-α induces blood vessel growth in an in vivo assay [123].”
BackgroundThe Role of Cytokines in Breast Cancer Development and Progression
Esquivel-Velázquez, M., Ostoa-Saloma, P., Palacios-Arreola, M. I., Nava-Castro, K. E., Castro, J. I., & Morales-Montor, J. (2015) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2014.0026 · Cited by 490
Cofano, F., Boido, M., Monticelli, M., Zenga, F., Ducati, A., Vercelli, A., & Garbossa, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112698 · Cited by 398
Bronckaers, A., Hilkens, P., Martens, W., Gervois, P., Ratajczak, J., Struys, T., & Lambrichts, I. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.02.013 · Cited by 354
Role of Mesenchymal Stem Cells in Bone Regenerative Medicine: What Is the Evidence?
Oryan, A., Kamali, A., Moshiri, A., & Baghaban Eslaminejad, M. (2017) · Cells Tissues Organs · doi:10.1159/000469704 · Cited by 353
Stem cells as drug delivery methods: Application of stem cell secretome for regeneration
Tran, C., & Damaser, M. S. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.10.007 · Cited by 278
García-Bernal, D., García-Arranz, M., Yáñez, R. M., Hervás-Salcedo, R., Cortés, A., Fernández-García, M., Hernando-Rodríguez, M., Quintana-Bustamante, Ó., Bueren, J. A., García-Olmo, D., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.650664 · Cited by 138
Kerpedjieva, S. S., Kim, D. S., Barbeau, D. J., & Tamama, K. (2012) · Stem Cells and Development · doi:10.1089/scd.2011.0711 · Cited by 53
Metadata
- Authors
- De Luca, A., Gallo, M., Aldinucci, D., Ribatti, D., Lamura, L., D'Alessio, A., De Filippi, R., Pinto, A., & Normanno, N.
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2011-04-25
- Volume
- 226
- Issue
- 8
- Pages
- 2131-2138
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W2009891045
- Cited by
- 113
- References
- 10
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.